Results 71 to 80 of about 10,060 (149)

Real-World Experience with Canakinumab in Familial Mediterranean Fever: A Single-Center Study

Uludağ Üniversitesi Tıp Fakültesi Dergisi
Familial Mediterranean fever (FMF) is an autoinflammatory disorder caused by mutations in the Mediterranean fever gene (MEFV), leading to excessive interleukin-1 beta (IL-1β) production.
Tuğba Ocak, Ayşe Bulur, Burcu Yağız, Belkis Nihan Coskun, Hüseyin Ediz Dalkılıç, Yavuz Pehlivan   +5 more
doaj   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Volume 78, Issue 10, Page 1317-1323, October 2026.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system

Frontiers in Pharmacology
BackgroundAnakinra and canakinumab are two FDA-approved IL-1 blockers indicated for the treatment of multiple autoinflammatory diseases, yet their safety has not been comprehensively analyzed.
Hao Liu, Wei Yan, Jinsong Li, Dezhi Yan, Di Luo   +4 more
doaj   +1 more source

Canakinumab for Atherosclerotic Disease [PDF]

New England Journal of Medicine, 2018
Rothman, A.M., Morton, A., Crossman, D.
openaire   +11 more sources

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Pediatric Rheumatology Online Journal
Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement.
Lingzhi Qiu, Le Ma, Yifan Xie, Jing Jin, Yuting Pan, Shumin Li, Zhidan Fan, Haiguo Yu   +7 more
doaj   +1 more source

Treatment of systemic-onset juvenile arthritis with canakinumab

Open Access Rheumatology: Research and Reviews, 2015
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neonatology, Asklepios Clinic, Sankt Augustin, Germany Abstract: Treatment of systemic-onset juvenile idiopathic arthritis is challenging, but the ...
Peitz J, Horneff G
doaj  

Canakinumab dosing intervals in pediatric colchicine-resistant FMF: outcomes and predictors of successful extension in a real-world cohort. [PDF]

Rheumatology (Oxford)
Akay N, Barut K, Kosa B, Mert EN, Torunoglu Z, Aslan E, Gul U, Kilic Konte E, Yildiz M, Sahin S, Kasapcopur O.   +10 more
europepmc   +1 more source

Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials. [PDF]

Commun Med (Lond)
Platzbecker AS, Zoldan K, Brauer D, Kiewe P, Sasca D, Sockel K, Illmer T, Giagounidis A, Nowak D, Rieger K, Wortmann F, Götze K, Schmidt-Hieber M, Mayer K, Vehling-Kaiser U, Weide R, Mahlmann S, Przybilla J, Melzer S, Cross M, Schneider M, Hasenclever D, Metzeler KH, Platzbecker U.   +23 more
europepmc   +1 more source

Breaking the storm: canakinumab as salvage therapy for refractory macrophage activation syndrome in pediatric systemic lupus erythematosus-a case report. [PDF]

Pediatr Rheumatol Online J
Selvarajan T, Kannekanti L, Green A, Smith AZ, Umer S.   +4 more
europepmc   +1 more source

Age-Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database. [PDF]

Pharmacol Res Perspect
Wang Y, Lam N, Huang X, Jiao Y.
europepmc   +1 more source